Literature DB >> 26912552

Rethinking First-Line Immunosuppression for Idiopathic FSGS.

Jordana B Cohen1, Jonathan J Hogan2.   

Abstract

Entities:  

Keywords:  Immune Tolerance; focal segmental glomerulosclerosis; glomerular disease; immunosuppression; treatment

Mesh：

Year:  2016        PMID： 26912552      PMCID： PMC4791829          DOI： 10.2215/CJN.00780116

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  21 in total

1.  Marginal structural models and causal inference in epidemiology.

Authors:  J M Robins; M A Hernán; B Brumback
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

2.  Treatment of primary focal segmental glomerulosclerosis.

Authors:  Stephen M Korbet
Journal:  Kidney Int       Date:  2002-12       Impact factor: 10.612

3.  Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.

Authors:  Louis-Philippe Laurin; Adil M Gasim; Caroline J Poulton; Susan L Hogan; J Charles Jennette; Ronald J Falk; Bethany J Foster; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-16       Impact factor: 8.237

4.  Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study.

Authors:  Dimitrios S Goumenos; George Tsagalis; A Meguid El Nahas; John R Shortland; Periklis Davlouros; John G Vlachojannis; Colin B Brown
Journal:  Nephron Clin Pract       Date:  2006-06-19

Review 5.  Pathologic classification of focal segmental glomerulosclerosis.

Authors:  Vivette D'Agati
Journal:  Semin Nephrol       Date:  2003-03       Impact factor: 5.299

6.  Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy.

Authors:  Neill Duncan; Ajay Dhaygude; Jane Owen; Thomas D H Cairns; Megan Griffith; Adam G McLean; Andrew Palmer; David Taube
Journal:  Nephrol Dial Transplant       Date:  2004-10-26       Impact factor: 5.992

7.  Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?

Authors:  C Ponticelli; M Villa; G Banfi; B Cesana; C Pozzi; A Pani; P Passerini; M Farina; C Grassi; A Baroli
Journal:  Am J Kidney Dis       Date:  1999-10       Impact factor: 8.860

Review 8.  The treatment of idiopathic focal segmental glomerulosclerosis in adults.

Authors:  Jonathan Hogan; Jai Radhakrishnan
Journal:  Adv Chronic Kidney Dis       Date:  2014-09       Impact factor: 3.620

9.  Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis.

Authors:  V J Savin; R Sharma; M Sharma; E T McCarthy; S K Swan; E Ellis; H Lovell; B Warady; S Gunwar; A M Chonko; M Artero; F Vincenti
Journal:  N Engl J Med       Date:  1996-04-04       Impact factor: 91.245

10.  Long-term outcome in children and adults with classic focal segmental glomerulosclerosis.

Authors:  D C Cattran; P Rao
Journal:  Am J Kidney Dis       Date:  1998-07       Impact factor: 8.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.